Loading
A phase 2/3 trial of Disitamab vedotin and Cadonilimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy is a phase 2/3 interventional study registered as NCT06221748 by RemeGen Co., Ltd., with 90 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-12. Interventions recorded: Disitamab Vedotin Injection, Cadonilimab Injection and Paclitaxel Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RemeGen, Disitamab vedotin, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/